Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation

Campa, Daniele; Pastore, Manuela; Capurso, Gabriele; Hackert, Thilo; Leo, Milena Di; Izbicki, Jakob R.; Khaw, Kay Tee; Gioffreda, Domenica; Kupčinskas, Juozas; Pasquali, Claudio; Mačinga, Peter; Kaaks, Rudolf; Stigliano, Serena; Peeters, Petra H.M.; Key, Timothy J.; Talar-Wojnarowska, Renata; Vodička, Pavel; Valente, Roberto; Vashist, Yogesh K.; Salvia, Roberto; Papaconstantinou, Ioannis; Shimizu, Yasuhiro; Valsuani, Chiara; Zambon, Carlo–Federico; Gazouli, Maria; Valantienė, Irena; Niesen, Willem; Mohelníková-Duchoňová, Beatrice; Hara, Kazuo; Souček, Pavel; Małecka‐Panas, Ewa; Bueno-de-Mesquita, H. Bas; Johnson, Theron; Brenner, Hermann; Tavano, Francesca; Fogar, Paola; Ito, Hidemi; Sperti, Cosimo; Butterbach, Katja; Andriulli, Angelo; Cavestro, Giulia Martina; Busch, Olivier R.; Dijk, Frederike; Greenhalf, William; Matsuo, Keitaro; Lombardo, Carlo; Strobel, Oliver; König, Anna Katharina; Ćuk, Katarina; Strothmann, Hendrik; Katzke, Verena; Cantore, Maurizio; Mambrini, Andrea; Oliverius, Martin; Pezzilli, Raffaele; Landi, Stefano; Canzian, Federico

doi:10.1002/ijc.31047

Cited by 14 publications

(10 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, both pancreatic cancer tissue and CP have same dysregulated signaling pathways, such as nuclear factor kappa B, cytokines, peroxisome proliferator-activated receptor-γ, as well as reactive oxygen species [15]. However, there is possibly no identical genetic susceptibility between pancreatic cancer and CP, at least in the variants with high frequency [16].…”

Section: Discussionmentioning

confidence: 99%

Risk of pancreatic cancer in patients undergoing surgery for chronic pancreatitis

et al. 2019

View full text Add to dashboard Cite

Background Chronic pancreatitis (CP) is considered to be a risk factor for pancreatic cancer. A retrospective study was conducted to evaluate the incidence of pancreatic cancer after surgery for CP and to determine the risk factors. Methods The patients who underwent surgery for histologically documented CP between January 2009 and December 2017 were reviewed. The baseline characteristics, operative data, postoperative complications, and follow-up information were analysed. We calculated standardized incidence ratio on the base of the incidence of pancreatic cancer in the standard population in China. The risk factor for pancreatic cancer was assessed using Cox regression. Results Among 650 patients, pancreatic cancer was detected in 12 patients (1.8%) after a median follow-up of 4.4 years. The standardized incidence ratio of pancreatic cancer was 68.12 (95% CI, 35.20–118.99). Two independent risk factors for the development of pancreatic cancer in patients with chronic pancreatitis after surgery were identified: time interval to surgery [HR 1.005, 95% CI (1.002–1.008), P = 0.002] and de novo endocrine insufficiency [HR 10.672, 95% CI (2.567–44.372), P = 0.001]. Conclusions Patients who require surgery for CP are at a very high risk of developing pancreatic cancer. Early surgical intervention plays a protective role in the development of pancreatic cancer from CP. A high index of suspicion for pancreatic cancer should be maintained in CP patients with de novo postoperative diabetes after surgery.

show abstract

Section: Discussionmentioning

confidence: 99%

Risk of pancreatic cancer in patients undergoing surgery for chronic pancreatitis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Previous studies revealed that the processes of genotype accumulation and clonal expansion are required for the development of invasive PDAC (11,16,20). Many efforts have been made to identify gene mutations associated with pancreatic cancer, including mutL homolog 1 and PMS1 homolog 1, mismatch repair system component (21), and BRCA1/2 DNA repair (22).…”

Section: Discussionmentioning

confidence: 99%

PRSS1 genotype is associated with prognosis in patients with pancreatic ductal adenocarcinoma

Ding

Chen

et al. 2019

Oncol Lett

View full text Add to dashboard Cite

The prognostic value of the genotype of the PRSS1 gene in patients with pancreatic ductal adenocarcinoma (PDAC) remains poorly understood. The aim of the present study was to evaluate the association between the PRSS1 genotype and clinicopathological characteristics of patients with PDAC, as well as to explore the prognostic significance of the PRSS1 genotype in patients with PDAC. A total of 124 patients with PDAC patients were included in the current study and the PRSS1 genotype of the enrolled patients was determined by the polymerase chain reaction. Associations between the PRSS1 genotype and clinicopathological characteristics were subsequently analyzed using the Chi-square test. The impact of the PRSS1 genotype on patient prognosis was assessed using the Kaplan-Meier method, and predictive factors of overall survival (OS) time were analyzed by Cox regression. A total of 56 patients with PDAC (45.16%) had the T/C PRSS1 genotype, which was associated with large tumor sizes (P=0.027) and higher tumor node metastasis (TNM) stages (P=0.041). Following a median follow-up of 19 months, the T/C genotype of PRSS1 genotype was associated with a shorter OS time (P=0.037) compared with the C/C or T/T PRSS1 genotypes. Univariate and multivariate analyses revealed that PRSS1 genotype was identified to be an independent prognostic factor for the OS time of patients with PDAC. The results obtained in the current study suggested that the PRSS1 genotype, as well as factors such as the serum level of carbohydrate antigen 19-9 and the TNM stage, may act as independent prognostic factors for the OS time of patients with PDAC.

show abstract

“…Additionally, biomarkers like Glypican-1, CD63, and miR-451a exosomes seem to be promising [87,88,89]. Nevertheless, in the development of successful biomarkers, it needs to be noted that predispositions such as chronic pancreatitis and pancreatic cancer may have different genetic abnormalities [90]. …”

Section: Procedures Of Screeningmentioning

confidence: 99%

Familial Pancreatic Cancer

Benzel

Fendrich

2018

Oncol Res Treat

View full text Add to dashboard Cite

Familial pancreatic cancer accounts for 10% of all patients with pancreatic cancer. Because the 5-year survival rate of pancreatic cancer is only 7%, screening programs for high-risk individuals are essential and might be advantageous. Pancreatic ductal adenocarcinoma mostly shows symptoms at an advanced state and treatment is not efficient enough to cure most patients. People with hereditary tumor syndromes or their affected relatives can also be included in such screening programs. Besides the collection of data to investigate the background of the disease, these screening programs aim to diagnose and treat precursor lesions so that more dangerous, invasive lesions are prevented. These precursor lesions can be pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasm, and mucinous cystic neoplasm. This review summarizes the latest knowledge of pancreatic screening programs, shows the procedure of pancreatic cancer screening, and gives an overview of current guidelines.

show abstract

Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation

Cited by 14 publications

References 34 publications

Risk of pancreatic cancer in patients undergoing surgery for chronic pancreatitis

Risk of pancreatic cancer in patients undergoing surgery for chronic pancreatitis

PRSS1 genotype is associated with prognosis in patients with pancreatic ductal adenocarcinoma

Familial Pancreatic Cancer

Contact Info

Product

Resources

About